Follow-up with CA125 after primary therapy of advanced ovarian cancer: In favor of continuing to prescribe CA125 during follow-up

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 40-44

  Pignata, S ^a   Cannella, L ^a   Leopardo, D ^a   Bruni, G S ^a   Facchini, G ^a   Pisano, C ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CA125; Follow up; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; PAZOPANIB; SORAFENIB; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FOLLOW UP; HUMAN; INTESTINE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; BLOOD; FEMALE; METHODOLOGY; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; WATCHFUL WAITING;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84857401263     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr470     Document Type: Conference Paper

References (29)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59: 225-249.
2. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337.
3. Rustin GJ, Bast RCJ, Kelloff GJ et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10:3919-3926.
4. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
5. Rustin GJS, Nelstrop AE, Bentzen SM et al. Selection of active drugs for ovarian cancer based on CA 125 and standard response rates to phase II trials. J Clin Oncol 2000; 18: 1733-1739.
6. Rustin GJ, Quinn M, Thigpen T et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96:487-488.
7. Gronlund B, Høgdall C, Hilden J et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004; 22: 4051-4058.
8. Van Dalen A, Favier J, Burges A et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000; 79: 444-450.
9. Høgdall CK, Norgaard-Pedersen B, Mogensen O. The prognostic value of preoperative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res 2002; 22: 1765-1768.
10. Hawkins RE, Roberts K, Wiltshaw E et al. The prognostic significance of the halflife of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989; 96: 1395-1399.
11. Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423-429.
12. Zorn KZ, Tian C, McGuire WP et al. Prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. Cancer 2009; 115: 1028-1035.
13. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005; 16:47-50.
14. Van Altena AM, Kolwijck E, Spanjer MJB et al. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer:a population-based study. Gynecol Oncol 2010; 119: 265-269.
15. Van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301-302.
16. Rustin GJS, Timmers P, Nelstrop A et al. Comparison of ca-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide J. Clin Oncol 2006; 24: 45-51.
17. Rustin GJ, Marples M, Nelstrop AE et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19: 4054-4057.
18. Gu P, Pan LL, Wu SQ et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009; 71: 164-174.
19. Bristow RE, Giuntoli RL, Pannu HK et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005; 99: 294-300.
20. Rustin GJS, van der Burg MEL, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.
21. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-968.
22. Fleming ND, Cass I, Walsh CS et al. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 121: 249-252.
23. Tanner JE, Chi DS, Eisenhauer EL et al. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol 2010; 117: 336-340.
24. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer:a meta-analysis. Gynecol Oncol 2009; 112: 265-274.
25. Harter P, DuBois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the AGO DESKTOP OVAR Trial. Ann Surg Oncol 2006; 13: 1702-1710.
26. Azad NS, Annunziata CM, Steinberg SM et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 2008;112: 1726-1732.
27. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.J Clin Oncol 2008; 26: 3709-3714.
28. Friedlander M, Trimble E, Tinker A et al. clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011; 21: 771-775.
29. Friedlander MKC, Hancock B, Rischin D et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119: 32-37.